AuraSense Therapeutics Closes $13.6M Series C Financing

AuraSense Therapeutics, a Chicago, IL-based biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, closed a $13.6m Series C financing.

Backers included current investors Patrick Ryan, founder of Aon; David Walt, co-founder of Illumina and a Company Director; Boon Hwee Koh, Director of Agilent Technologies and former Chairman of Singapore Airlines; Craig Mundie, Senior Advisor to the CEO of Microsoft; and new investors the Rathmann Family Foundation and Bill Gates.

The company intends to use the funds to further develop and advance several novel SNA-based constructs into human trials.

Led by Dr. David Giljohann, Chief Executive Officer, and Dr. Sergey Gryaznov, Chief Technology Officer, AuraSense Therapeutics develops therapies based upon its proprietary Spherical Nucleic Acid (SNA™) gene regulation and immune modulation strategies. The company has a core focus on debilitating diseases with limited or no treatment options.
SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology.



Join the discussion